Efficiency, Safety and Portability of Neovasculgen

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT03068585

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Artgen Biotech (from the registry)
Registry
  • NCT NCT03068585
Other papers using this trial's data
  • Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication Therapeutic advances in cardiovascular disease, 2018-09 DOI, PubMed 29996720, PMC6116753 Not in the PMC Open Access subset.
  • pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia Journal of cardiovascular pharmacology and therapeutics, 2015-09 DOI, PubMed 25770117

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03068585. Randomized; no masking; primary purpose treatment. Start 2010-02 (actual); primary completion 2011-06-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficiency, Safety and Portability of Neovasculgen
Acronym
Neovasculgen
Condition
Peripheral Arterial Disease
Intervention (Drug)
Neovasculgen (Cambiogeneplasmid)
Lead sponsor
Artgen Biotech (class: other)

Record details

Record id
cardio:ct-nct03068585
Content hash
93d19d511b8ced8002a3fdda5172ac67e47ff3fa7044849e869681fd6c28a651